Conquer Cancer Logo

Based on funding availability, a limited number of Merit Awards will be awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO Meeting and recognized for its scientific merit.

Merit Award recipients are honored with the opportunity to present their abstract at the Meeting, receive $1,000 in monetary support, complimentary registration for the Meeting, and access to reserved Meeting hotel reservation blocks. Merit Award candidates must apply for this award at the time of abstract submission.

For the ASCO Annual Meeting Merit Awards, Conquer Cancer has dedicated funds for the following areas and groups: breast cancer, gastrointestinal cancer, geriatric oncology, genitourinary cancer, lung cancer, female lung cancer researchers and researchers from Florida and outside the United States. Abstracts in other types of oncology-related research are also highly encouraged.


Applicants must meet the following criteria to be considered for a Merit Award:

  • Be the First Author on the abstract submission and agree to present the abstract if selected for presentation at the Meeting
  • Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD)
  • Be enrolled in an oncology fellowship training program, a radiation oncology residency program, or an equivalent oncology training program at the time of abstract submission
  • Work in an oncology laboratory or clinical research setting
  • Provide a letter of support from their training program director, indicating eligibility for the award
  • Provide a curriculum vitae

Special Merit Awards

Special Merit Awards are presented each year to trainees and junior faculty who have the top-ranking abstracts for the ASCO Annual Meeting. In addition to the stipend, recipients receive a plaque and are recognized at the ASCO Annual Meeting.

Bradley Stuart Beller Endowed Merit Award ($2,000)

This award is given to the fellow who has the highest ranking abstract overall in the Merit Award category as determined by the Scientific Program Committee.

Brigid Leventhal Special Merit Award ($1000)

This award is given to the fellow who submitted the top abstract in Pediatric Oncology as determined by the Scientific Program Committee.

Pain and Symptom Management Special Merit Award ($1000)

This award is given to the fellow who submitted the top abstract in Pain and Symptom Management Research as determined by the Scientific Program Committee.

Allen S. Lichter, MD Endowed Merit Award ($1000)

This award is given to the fellow who has the second highest ranking abstract in the Merit Award category as determined by the Scientific Program Committee.

James B. Nachman Endowed ASCO Junior Faculty Award in Pediatric Oncology ($3,000)

This award was established in memory of James B. Nachman, MD, Professor of Pediatrics at the University of Chicago and an internationally renowned pediatric cancer expert. It is endowed through the James B. Nachman Pediatric Oncology Fund and will be given each year to a junior faculty member who submits the highest ranking abstract in pediatric oncology for the ASCO Annual Meeting as determined by the ASCO Scientific Program Committee. The recipient will receive $3,000 in monetary support to attend the Annual Meeting, complimentary registration for the Annual meeting and access to reserved Meeting housing. Candidates must apply for this award at the time of abstract submission.

The First Author must meet all of the following requirements to be considered for the James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology:

  • Hold a medical or doctoral degree (MD, PhD, DO, or DNP)
  • Be within 7 years of their first faculty appointment at the time of abstract submission
  • Conduct laboratory, population-based, or clinical research focused on childhood cancer
  • Agree to present the abstract at the ASCO Annual Meeting
  • In addition, the abstract must be selected for presentation in an Oral Abstract Session

Application Instructions

Consideration for a Merit Award is available on the abstract submitter for the ASCO Annual Meeting and other ASCO thematic meetings.

Abstract Submission Deadlines:

  • 2020 Gastrointestinal Cancers Symposium: October 1, 2019, at 11:59 PM EDT
  • 2020 ASCO-SITC Clinical Immuno-Oncology Symposium: October 15, 2019 at 11:59 PM EDT
  • 2020 Genitourinary Cancers Symposium: October 22, 2019, at 11:59 PM EDT
  • 2020 ASCO Annual Meeting: February 11, 2020 at 11:59 PM EST
  • 2020 Palliative and Supportive Care in Oncology Symposium: TBD
  • 2020 ASCO Quality Care Symposium: TBD

For Merit Award eligibility and application questions, please contact

2019 Annual Meeting Merit Award Recipients

Zaid Abdel Rahman, MD
Mayo Clinic
Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort (MCAEC).
Jithma Abeykoon, MD
Mayo Clinic
Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).
Sarah Abou Alaiwi, MD
Dana–Farber Cancer Institute
Association of polybromo-associated baf (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).
Iman Aboudalle, MD
The University of Texas M.D. Anderson Cancer Center
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.
Nour Abuhadra, MD
The University of Texas M.D. Anderson Cancer Center
Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.
Mihaela Aldea, MD, PhD
Gustave Roussy
Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.
Mansour Alfayez, MD, MS
The University of Texas M.D. Anderson Cancer Center
Smoking is associated with poor risk ELN 2017, cytogenetics/molecular profile, and confers poor survival outcomes in acute myeloid leukemia.
Kartik Anand, MBBS
Houston Methodist Cancer Center
Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.
Avani Athauda, MBBS
The Royal Marsden Hospital
Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).
Florence Atrafi, MD, MSc
Maastricht University
A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.
Dilip Babu, MD
University of Rochester
Associations of uncertainty with psychological status and quality of life (QoL) among 527 older patients with advanced cancer.
Marco Bandini, MD
Vita-Salute San Raffaele University
Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.
Francesca Battaglin, MD
University of Southern California
Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.
Jacob Berchuck, MD
Dana-Farber Cancer Institute
Disparities in lung cancer outcomes for veterans with comorbid mental disorders.
David Bond, MD
The Ohio State University
Second cancer incidence in CLL patients receiving BTK inhibitors.
Sam Brondfield, MD
University of California, San Francisco
Feasibility of implementing a resident oncology video curriculum.
Maria Alessandra Calegari, MD
Oncologia Medica, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS
Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).
Kamal Chamoun, MD
University Hospitals Seidman Cancer Center
Insurance status and survival of multiple myeloma (MM) patients.
Bhavana Chapman, MD
The University of Texas M.D. Anderson Cancer Center
Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: A large, single-institutional experience.
Fo-Ping Chen, PhD
Sun Yat-sen University
Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epstein–Barr virus DNA and TNM stage: A “Big data” analysis of 9,160 endemic cases.
Kelly Chien, MD, BS
The University of Texas M.D. Anderson Cancer Center
Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes.
Dai Chihara, MD, PhD
National Cancer Institute
Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.
Mudit Chowdhary, MD
Rush University Medical Center
Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?
Julie Collins, MD, MPH
National Cancer Institute
Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.
Vincenza Conteduca, MD, PhD
Dana-Farber Cancer Institute
SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) predicts response to platinum-based chemotherapy (PLT).
Colleen Cuthbert, PhD
University of Calgary
Patient level factors associated with chronic opioid use in cancer patients.
Antonio Di Meglio, MD
Institut Gustave Roussy
Impact of overweight, obesity and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.
Brunella Di Stefano, MD
Fondazione Policlinico Universitario A. Gemelli-IRCCS-UOC Oncologia Medica
Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).
Stephanie Dixon, MD, BS
St. Jude Children's Research Hospital
Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.
Nazli Dizman, MD
City of Hope
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
Narjust Duma, MD
Mayo Clinic
Evaluating unconscious bias: Speaker introductions at an international oncology conference.
Lawson Eng, MD
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre
Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.
Kelly Faulk, MD
University of Colorado
Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.
Roberto Ferrara, MD
Istituto Nazionale dei Tumori
Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).
Arlindo Ferreira, MD, MSc
Institut Gustave Roussy
Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.
Adriana Fonseca, MD
The Hospital for Sick Children
Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy.
Jason Frankel, MD
Virginia Mason Medical Center
Contemporary trends in treatment for low-risk prostate cancer.
Ehsan Ghorani, MBBS
University College London Cancer Institute
Imbalance between early and late differentiated intra-tumour CD4 T cells is associated with mutational burden in non-small cell lung cancer.
Smith Giri, MBBS
Yale School of Medicine
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Ashley Graul, MD
University of Pennsylvania
Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care service among gynecologic oncology patients.
Robin Guo, MD
Memorial Sloan Kettering Cancer Center
MET inhibitor resistance in patients with MET exon 14-altered lung cancers.
Sumit Gupta, MD, PhD
Hospital for Sick Children
Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the children’s oncology group (COG).
Andrew Hahn, MD
University of Utah
Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).
Evan Hall, MD, MPhil
Stanford University
Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
Anis Hamid, MBBS
Dana-Farber Cancer Institute
Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).
Ross Harrison, MD
The University of Texas M.D. Anderson Cancer Center
Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer.
Caroline Hesko, MD, MPH, BS
University of Chicago
Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.
Evthokia Hobbs, MD
The University of Texas M.D. Anderson Cancer Center
Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation.
Joshua Horton, MD
Medical University of South Carolina
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
Liang Huang, MD, PhD
Huazhong University of Science and Technology
Efficacy and safety of CAR19/22 t-cell “cocktail” therapy in patients with refractory/relapsed b-cell non-Hodgkin lymphoma.
Marco Iafolla, MD
Princess Margaret Cancer Centre
Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P).
Vikram Jairam, MD
Yale University
Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer.
Emre Koca, MD
Houston Methodist Hospital
Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.
Igal Kushnir, MD
Ottawa Hospital Cancer Centre
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).
Matteo Lambertini, MD
University of Genova
Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.
Alessandro Leal, MD
Johns Hopkins University
Genome-wide cell-free DNA fragmentation profiling for early cancer detection.
Po-Ju Lin, PhD, MPH, RD
University of Rochester Medical Center
Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.
Kah Poh Loh, MBBCh
University of Rochester
Prognostic understanding in hematologic malignancies: A multicenter longitudinal study.
Ethan Ludmir, MD
The University of Texas M.D. Anderson Cancer Center
Age disparities among cancer clinical trial participants: The role of industry sponsorship.
Stephen Luen, MBChB
Peter MacCallum Cancer Centre
On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.
Jelena Lukovic, MD, MPH
Princess Margaret Cancer Centre
Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.
Jia-Wei Lv, MD
Sun Yat-sen University Cancer Center
Longitudinal Circulating Epstein–barr virus DNA Response to Induction Chemotherapy and Chemo-radiotherapy Identifies Distinct Biological Phenotypes in EBV-associated Nasopharynx of Head and Neck Cancer.
Eoghan Malone, MBBCh
Mater Misericordiae University Hospital
Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
Hiren Mandaliya, MD, MBBS, FRACP
Calvary Mater Newcastle Hospital
Mortality within 30 days of immunotherapy (checkpoint inhibitors) in metastatic cancer patients treated at Australian tertiary cancer center.
Federica Marmorino, MD
Azienda Ospedaliera Universitaria Pisana
Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.
Deborah Marshall, MD
Icahn School of Medicine at Mount Sinai
Trends in financial relationships between industry and individual medical oncologists in the United States from 2014 to 2017: A cohort study.
Jingjing Miao, MSc
Sun Yat-sen University
A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.
Orli Michaeli, MD
Hospital for Sick Children
Gliomas in the context of Li-Fraumeni syndrome: An international cohort.
Arjun Mittra, MBBS
National Cancer Institute
Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.
Leslie Modlin, MD
Memorial Sloan Kettering Cancer Center
Breast radiotherapy among ATM-mutation carriers.
Sebastián Mondaca, MD
Memorial Sloan Kettering Cancer Center
Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer.
Madiha Naseem, MD
Unversity of Southern California
BRCA1 genetic variant predicts survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase IIII TRIBE and FIRE-3 trials.
Maliha Nusrat, MD
The University of Texas M.D. Anderson Cancer Center
Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).
Ben O'Leary, MBBS
The Institute of Cancer Research
Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.
Daniel Olson, MD
University of Chicago
Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).
Carina Owen, MBBS
Melanoma Institute Australia
A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.
Kaushal Parikh, MD
Mayo Clinic
Low nationwide utilization of adjuvant chemotherapy (AC) in elderly patients with localized non-small cell lung cancer (NSCLC).
Woochan Park, MD
Seoul National University Hospital
Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.
Alec Paschalis, MBBS BSc
The Institute of Cancer Research
PSMA heterogeneity and DNA repair defects in prostate cancer.
Javier Pascual, MD
Royal Marsden Hospital and The Institute of Cancer Research
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
Ranjan Pathak, MBBS
Yale School of Medicine
Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.
Meredith Pelster, MD, MSCI
The University of Texas M.D. Anderson Cancer Center
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
Kirstin Perdrizet, MD
University of Toronto
Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.
Isabel Pimentel, MD
Mount Sinai Hospital, University of Toronto
The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.
David Pinato, MD, PhD, MRCP
Imperial College London
Molecular characterization of the tumour microenvironment in neuroendocrine malignancy.
Ines Pires Da Silva, MD
Melanoma Institute Australia
Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.
YaoYao Pollock, MD
University of California, San Francisco
Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).
Pradeep Poonnen, MD, MPH
Duke University
Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.
Hanneke Poort, PhD
Dana-Farber Cancer Institute
Predictors and trajectories of fatigue in ovarian and uterine cancer.
Prateek Prasanna, PhD
Case Western Reserve University
Intra and perinodular CT delta radiomic features associated with early response can predict overall survival (OS) in immunotherapy-treated non-small cell lung cancer (NSCLC): A multi-site multi-agent study.
Robert Press, MD
Department of Radiation Oncology, Winship Cancer Institute of Emory University
The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma.
Alberto Puccini, MD
University of Southern California
Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).
Hind Rafei, MD
The University of Texas M.D. Anderson Cancer Center
Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients.
Irbaz Bin Riaz, MBBS, MS
Mayo Clinic
A living systematic review of immune checkpoint inhibitors in cancer patients: A novel platform for evidence synthesis in oncology.
Biagio Ricciuti, MD
Dana-Farber Cancer Institute
DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.
Daniel Richardson, MD, MA
The Cecil G. Sheps Center for Health Services Research
Development of an “Art of Oncology” curriculum to mitigate burnout and foster solidarity among hematology/oncology fellows.
Felicia Roncolato, FRACP, MBChB, PhD
Macarthur Cancer Therapy Centre
How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).
Daniele Rossini, MD
Azienda Ospedaliera Universitaria Pisana
Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.
Maria Rubinstein, MD
Memorial Sloan Kettering Cancer Center
A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.
Adam Schoenfeld, MD
Memorial Sloan Kettering Cancer Center
Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.
Julia Schwarze, MD
Universitair Ziekenhuis Brussel
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
Andreas Seeber, MD, PhD
Medizinische Universität Innsbruck 
BRCA-mutant pancreatic cancer is associated with high tumor mutational burden (TMB) and higher PD-L1 expression.
Matthew Seidler, MDCM
Massachusetts General Hospital
Impact of a same-day breast biopsy program on disparities in time to biopsy.
Iris Sheng, MD
Cleveland Clinic
Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration.
Mina Shenouda, MBBch
Marshall University
Effect of tart cherry on aromatase inhibitor-induced arthralgia (AIA) in nonmetastatic hormone-positive breast cancer patients: A randomized double-blind placebo-controlled trial.
Ramila Shilpakar, MD
NAMS, Bir hospital
Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate cancer pain.
Mahran Shoukier, MD
The University of Texas M.D. Anderson Cancer Center
Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.
Surbhi Sidana, MD
Mayo Clinic
Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).
Jay Spiegel, MD, FRCPC
Stanford University
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.
Marissa Srour, MD
Cedars-Sinai Medical Center
Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis.
Tessa Steenbruggen, MD
Netherlands Cancer Institute
Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC).
Paul Stewart, MBBS
Western University
Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.
Paolo Strati, MD
The University of Texas M.D. Anderson Cancer Center
Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
Ryuma Tokunaga, MD, PhD
University of Southern California
Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.
Davis Torrejon, MD
University of California, Los Angeles
Overcoming genetically-based resistance mechanisms to PD-1 blockade.
Panagiotis Vlachostergios, MD, PhD
Weill Cornell Medical College
Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.
Natalie Vokes, MD, MPhil
Dana-Farber Cancer Institute
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB).
Yucai Wang, MD, PhD
Mayo Clinic
Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.
Yuefeng Wang, MD, D.Phil
University of Tennessee
Association of total hysterectomy with survival among newly diagnosed uterine cancer patients with distant organ metastasis.
AnnaLynn Williams, PhD
University of Rochester Medical Center
Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation.
Jason Willis, MD, PhD
The University of Texas M.D. Anderson Cancer Center
Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing.
Juliet Wolford, MD
University of California, Irvine
SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).
Michael Xiang, MD, PhD
Stanford University
Risk of subsequent cancer diagnosis in patients treated with 3D conformal, intensity modulated, or proton beam radiation therapy.
Hao Xie, MD, PhD
Mayo Clinic
Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.
Yuan Xu, MD, PhD
University of Calgary
Association of providers’ prescribing patterns with postsurgical opioid use among cancer patients undergoing curative-intent surgery.
Siddhartha Yadav, MD, FACP
Mayo Clinic
Racial and ethnic differences in the results of multigene panel testing of inherited cancer predisposition genes in breast cancer patients.
Yunfang Yu, MD
Sun Yat-sen University
Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small-cell lung cancer (POPLAR and OAK): A combined analysis of two multicentre, randomized, phase II/III trials.
Saurabh Zanwar, MBBS, MD
Mayo Clinic
Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.
Bo Zhang, MD
Chinese Academy of Medical Sciences and Peking Union Medical College
Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.
Gemma Zucchelli, MD
Azienda Ospedaliera Universitaria Pisana
Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.


The Merit Award is supported by:


Agios Pharmaceuticals, Inc.
ASCO Employees
Association of Northern California Oncologists
Friends and Family of Dr. and Mrs. Ronald Beller
The Berry Family
Dr. and Mrs. Douglas W. Blayney
Jonathan K. and Cora Y. Cho Charitable Fund
Estate of Darla C. Ellis
G1 Therapeutics
Dr. Arti Hurria and Dr. Hyman B. Muss
Ipsen Biopharmaceuticals Inc.
Michael Kelley, MD, & Elise Hoffman, PharmD
Kidney Cancer Association
Friends and Family of Dr. James B. Nachman
Northern New England Clinical Oncology Society
Dr. Kathleen Pritchard Medicine Professional Corporation
Frances A. Shepherd, MD, FASCO
Stephen A. Sherwin, MD
Drs. Rachna and Puneet Shroff
Nizar M. Tannir, MD
Dr. Michael and Deborah Troner

This list reflects commitments as of April 29, 2019.

This grant receives support that may result in a report to the CMS Open Payments website under the Physician Payments Sunshine Act. The supporting companies are required to report the amount of the grant, the names of physicians who are awarded this grant, and the names of their institutions. This information may appear on the Open Payments websiteFind out more information about the Sunshine Act and CMS Open Payments program.